AIA Group Ltd Acquires New Holdings in United Therapeutics Co. (NASDAQ:UTHR)

AIA Group Ltd bought a new position in United Therapeutics Co. (NASDAQ:UTHR) in the 4th quarter, Holdings Channel.com reports. The fund bought 608 shares of the biotechnology company’s stock, valued at approximately $215,000.

Several other hedge funds also recently modified their holdings of the business. Newbridge Financial Services Group Inc. acquired a new position in United Therapeutics during the fourth quarter valued at approximately $25,000. Millstone Evans Group LLC acquired a new position in United Therapeutics in the 4th quarter valued at $67,000. MassMutual Private Wealth & Trust FSB grew its stake in United Therapeutics by 31.9% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock valued at $85,000 after buying an additional 58 shares during the last quarter. Jones Financial Companies Lllp raised its holdings in United Therapeutics by 678.9% in the 4th quarter. Jones Financial Companies Lllp now owns 296 shares of the biotechnology company’s stock worth $104,000 after acquiring an additional 258 shares during the period. Finally, SBI Securities Co. Ltd. bought a new stake in United Therapeutics during the fourth quarter valued at about $131,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Activity

In other news, COO Michael Benkowitz sold 10,000 shares of the firm’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $371.05, for a total value of $3,710,500.00. Following the completion of the sale, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $956,195.85. This trade represents a 79.51 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Tommy G. Thompson sold 2,500 shares of the company’s stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $318.80, for a total transaction of $797,000.00. Following the transaction, the director now owns 8,480 shares in the company, valued at approximately $2,703,424. This trade represents a 22.77 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 72,500 shares of company stock worth $26,134,500. Insiders own 11.90% of the company’s stock.

United Therapeutics Price Performance

United Therapeutics stock opened at $306.88 on Wednesday. The firm has a market capitalization of $13.78 billion, a P/E ratio of 13.48, a P/E/G ratio of 0.97 and a beta of 0.64. The stock has a fifty day moving average price of $337.82 and a two-hundred day moving average price of $355.39. United Therapeutics Co. has a 52-week low of $225.62 and a 52-week high of $417.82.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.10 by $0.09. The business had revenue of $735.90 million during the quarter, compared to analysts’ expectations of $734.74 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. During the same quarter last year, the company posted $4.36 EPS. On average, equities research analysts predict that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on UTHR shares. HC Wainwright reiterated a “buy” rating and issued a $425.00 price objective on shares of United Therapeutics in a research note on Thursday, February 27th. UBS Group lifted their price target on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. Finally, StockNews.com cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 27th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $388.25.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.